Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

ESMO Open. 2023 Apr;8(2):100778. doi: 10.1016/j.esmoop.2022.100778. Epub 2023 Feb 13.

Authors

S J Klempner¹, Y Y Janjigian², Z A Wainberg³

Affiliations

¹ Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, USA. Electronic address: [email protected].
² Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA.
³ Department of Medicine, Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, USA.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adenocarcinoma* / diagnosis
Adenocarcinoma* / pathology
Biomarkers
Esophageal Neoplasms* / diagnosis
Esophageal Neoplasms* / pathology
Humans

Substances

Biomarkers
CLDN18 protein, human